Skip to main content

Advertisement

Log in

Patient-reported outcomes in non-muscle invasive bladder cancer: a mixed-methods systematic review

  • Published:
Quality of Life Research Aims and scope Submit manuscript

Abstract

Objective

Non-muscle invasive bladder cancer (NMIBC) is a chronic condition requiring repeated treatment and endoscopic examinations that can occur life-long. In this context, patient-reported outcomes (PROs) are important considerations to patients and managing clinicians. We undertook a systematic review to synthesise PRO results relevant to NMIBC treatment to explore trajectories overtime and differences between treatment options.

Methods

We searched databases AMED, MEDLINE, EMbase, PsycINFO, Web of Knowledge and Scopus (inception to 5th December 2019), reference lists and contacted key authors to identify studies that reported PROs after NMIBC treatment. Two reviewers independently applied inclusion and quality criteria and extracted findings. Results for PROs were synthesised for treatment groups across three time periods: acute/during induction therapy; during maintenance therapy; and long-term follow-up (> 1 year).

Results

Of 3193 papers screened, 29 were eligible. These provided evidence about induction treatment effects, but few reported maintenance or long-term evidence, and evidence about differences between NMIBC treatment options was lacking. A range of symptoms (pain in bladder area, urinary frequency and urgency, pain or burning during urination) were commonly experienced during and soon after treatment for NMIBC. Less common symptoms included fatigue, disrupted sleep and gastrointestinal problems.

Conclusions

Treatments for NMIBC can cause symptoms and functional impairment during the acute treatment phase and reduce quality of life. Clinicians should be aware of these impairments to prepare patients for short-term sequelae and enable those with treatment options to exercise preferences in choosing among them. However, gaps in current evidence limit our understanding of PRO trajectories from diagnosis through to long-term survivorship and treatment effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Cheluvappa, R., Smith, D. P., Cerimagic, S., & Patel, M. I. (2014). A comprehensive evaluation of bladder cancer epidemiology and outcomes in Australia. International Urology and Nephrology, 46(7), 1351–1360.

    Article  Google Scholar 

  2. Heney, N. M. (1992). Natural history of superficial bladder cancer Prognostic features and long-term disease course. Urologic Clinics of North America, 19(3), 429–433.

    CAS  Google Scholar 

  3. Anastasiadis, A., & de Reijke, T. M. (2012). Best practice in the treatment of nonmuscle invasive bladder cancer. Therapeutic Advances in Urology, 4(1), 13–32. https://doi.org/10.1177/1756287211431976.

    Article  PubMed  PubMed Central  Google Scholar 

  4. US Department of Health & Human Support Food & Drug Administration. (2009). Patient reported outcome measures: Use in medical product development to support labelling claims. MD: US Department of Health & Human Support Food & Drug Administration.

    Google Scholar 

  5. Lipscomb, J., Gotay, C. C., & Snyder, C. F. (2007). Patient-reported outcomes in cancer a review of recent research and policy initiatives. CA: A Cancer Journal for Clinicians, 57(5), 278–300. https://doi.org/10.3322/ca.57.5.278.

    Article  Google Scholar 

  6. Metwally, M. A., Frederiksen, K. D., & Overgaard, J. (2014). Compliance and toxicity of the hypoxic radiosensitizer nimorazole in the treatment of patients with head and neck squamous cell carcinoma (HNSCC). Acta Oncologica, 53(5), 654–661. https://doi.org/10.3109/0284186x.2013.864050.

    Article  CAS  PubMed  Google Scholar 

  7. Hendricksen, K., Gleason, D., Young, J. M., Saltzstein, D., Gershman, A., Lerner, S., et al. (2008). Safety and side effects of immediate instillation of apaziquone following transurethral resection in patients with nonmuscle invasive bladder cancer. The Journal of urology, 180(1), 116–120. https://doi.org/10.1016/j.juro.2008.03.031.

    Article  CAS  PubMed  Google Scholar 

  8. Osoba, D., Zee, B., Pater, J., Warr, D., Latreille, J., & Kaizer, L. (1997). Determinants of postchemotherapy nausea and vomiting in patients with cancer Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology, 15(1), 116–123. https://doi.org/10.1200/jco.1997.15.1.116.

    Article  CAS  PubMed  Google Scholar 

  9. Botteman, M. F., Pashos, C. L., Hauser, R. S., Laskin, B. L., & Redaelli, A. (2003). Quality of life aspects of bladder cancer: a review of the literature. Quality of Life Research, 12(6), 675–688.

    Article  CAS  Google Scholar 

  10. Calvert, M., Brundage, M., Jacobsen, P. B., Schunemann, H. J., & Efficace, F. (2013). The CONSORT Patient-Reported Outcome (PRO) extension: implications for clinical trials and practice. Health Qual Life Outcomes, 11, 184. https://doi.org/10.1186/1477-7525-11-184.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Kmet, L., Lee, R., Cook, L., & Alberta Heritage Foundation for Medical Research. (2004). Standard quality assessment criteria for evaluating primary research papers from a variety of fields. Edmonton: Alta Alberta Heritage Foundation for Medical Research.

    Google Scholar 

  12. Centre for Reviews and Dissemination (2001). Undertaking systematic reviews of research on effectiveness. University of York. https://www.york.ac.uk/inst/crd/report4.htm.

  13. Colombo, R., Rocchini, L., Suardi, N., Benigni, F., Colciago, G., Bettiga, A., et al. (2012). Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non-muscle-invasive bladder cancer: preliminary results of a randomised phase 2 study. European Urology, 62(5), 797–802. https://doi.org/10.1016/j.eururo.2012.05.032.

    Article  CAS  PubMed  Google Scholar 

  14. Johnson, M. H., Nepple, K. G., Peck, V., Trinkaus, K., Klim, A., Sandhu, G. S., et al. (2013). Randomized controlled trial of oxybutynin extended release versus placebo for urinary symptoms during intravesical Bacillus Calmette-Guerin treatment. Journal of Urology, 189(4), 1268–1274. https://doi.org/10.1016/j.juro.2012.10.070.

    Article  CAS  Google Scholar 

  15. Mack, D., & Frick, J. (1996). Quality of life in patients undergoing bacille Calmette-Guerin therapy for superficial bladder cancer. British Journal of Urology, 78(3), 369–371.

    Article  CAS  Google Scholar 

  16. Steinberg, R. L., Thomas, L. J., Mott, S. L., O'Donnell, M., & A., (2019). Multi-perspective tolerance evaluation of bacillus calmette-guerin with interferon in the treatment of non-muscle invasive bladder cancer. Bladder Cancer, 5(1), 39–49. https://doi.org/10.3233/BLC-180203.

    Article  Google Scholar 

  17. Gontero, P., Oderda, M., Mehnert, A., Gurioli, A., Marson, F., Lucca, I., et al. (2013). The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guerin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial. Journal of Urology, 190(3), 857–862.

    Article  Google Scholar 

  18. Krajewski, W., Koscielska-Kasprzak, K., Rymaszewska, J., & Zdrojowy, R. (2017). How different cystoscopy methods influence patient sexual satisfaction, anxiety, and depression levels: a randomized prospective trial. Quality of Life Research.

  19. Van Der Aa, M. N. M., Steyerberg, E. W., Sen, E. F., Zwarthoff, E. C., Kirkels, W. J., Van Der Kwast, T. H., et al. (2007). Patients' perceived burden of cystoscopic and urinary surveillance of bladder cancer: A randomized comparison. BJU International, 101(9), 1106–1110. https://doi.org/10.1111/j.1464-410X.2007.07224.x.

    Article  PubMed  Google Scholar 

  20. Yokomizo, A., Kanimoto, Y., Okamura, T., Ozono, S., Koga, H., Iwamura, M., et al. (2016). Randomized Controlled Study of the Efficacy, Safety and Quality of Life with Low Dose bacillus Calmette-Guerin Instillation Therapy for Nonmuscle Invasive Bladder Cancer. Journal of Urology, 195(1), 41–46. https://doi.org/10.1016/j.juro.2015.08.075.

    Article  Google Scholar 

  21. Wei, L., Li, Q., Liang, H., & Jianbo, L. (2014). The quality of life in patients during intravesical treatment and correlation with local symptoms. Journal of Chemotherapy, 26(3), 165–168. https://doi.org/10.1179/1973947813y.0000000126.

    Article  PubMed  Google Scholar 

  22. Smith, A. B., Daneshmand, S., Patel, S., Pohar, K., Trabulsi, E., Woods, M., et al. (2019). Patient-reported outcomes of blue-light flexible cystoscopy with hexaminolevulinate in the surveillance of bladder cancer: results from a prospective multicentre study. BJU International, 123(1), 35–41. https://doi.org/10.1111/bju.14481.

    Article  CAS  PubMed  Google Scholar 

  23. Krajewski, W., Halska, U., Poletajew, S., Piszczek, R., Biezynski, B., Matyjasek, M., et al. (2018). Influence of transurethral resection of bladder cancer on sexual function, anxiety, and depression. Advances in Experimental Medicine and Biology, 1116, 37–50. https://doi.org/10.1007/5584_2018_264.

    Article  CAS  PubMed  Google Scholar 

  24. Topazio, L., Miano, R., Maurelli, V., Gaziev, G., Gacci, M., Iacovelli, V., et al. (2014). Could hyaluronic acid (HA) reduce Bacillus Calmette-Guerin (BCG) local side effects? Results of a pilot study. BMC Urology, 14, 64. https://doi.org/10.1186/1471-2490-14-64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Bohle, A., Balck, F., von Weitersheim, J., & Jocham, D. (1996). The quality of life during intravesical bacillus Calmette-Guerin therapy. Journal of Urology, 155(4), 1221–1226.

    Article  CAS  Google Scholar 

  26. Koga, H., Ozono, S., Tsushima, T., Tomita, K., Horiguchi, Y., Usami, M., et al. (2010). Maintenance intravesical bacillus Calmette-Guerin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: randomized controlled trial by the BCG Tokyo Strain Study Group. International Journal of Urology, 17(9), 759–766. https://doi.org/10.1111/j.1442-2042.2010.02584.x.

    Article  PubMed  Google Scholar 

  27. Schmidt, S., Frances, A., Lorente Garin, J. A., Juanpere, N., Lloreta Trull, J., Bonfill, X., et al. (2015). Quality of life in patients with non-muscle-invasive bladder cancer: one-year results of a multicentre prospective cohort study. Urologic Oncology, 33(1), 19.e17–15. https://doi.org/10.1016/j.urolonc.2014.09.012.

    Article  Google Scholar 

  28. Sabichi, A. L., Lee, J. J., Grossman, H. B., Liu, S., Richmond, E., Czerniak, B. A., et al. (2011). A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer. Cancer Prevention Research (Philadelphia, Pa), 4(10), 1580–1589. https://doi.org/10.1158/1940-6207.capr-11-0036.

    Article  CAS  PubMed Central  Google Scholar 

  29. Smith, A. B., Jaeger, B., Pinheiro, L. C., Edwards, L. J., Tan, H. J., Nielsen, M. E., et al. (2018). Impact of bladder cancer on health-related quality of life. BJU International, 121(4), 549–557. https://doi.org/10.1111/bju.14047.

    Article  PubMed  Google Scholar 

  30. Brisbane, W. G., Holt, S. K., Winters, B. R., Gore, J. L., Walsh, T. J., Wright, J. L., et al. (2019). Nonmuscle Invasive Bladder Cancer Influences Physical Health Related Quality of Life and Urinary Incontinence. Urology, 125, 146–153. https://doi.org/10.1016/j.urology.2018.11.038.

    Article  PubMed  Google Scholar 

  31. Danielsson, G., Malmstrom, P. U., Jahnson, S., Wijkstrom, H., Nyberg, T., & Thulin, H. (2018). Bladder health in patients treated with BCG instillations for T1G2-G3 bladder cancer-a follow-up five years after the start of treatment. Scandinavian Journal of Urology, 52(5–6), 377–384. https://doi.org/10.1080/21681805.2018.1538162.

    Article  CAS  PubMed  Google Scholar 

  32. Yoshimura, K., Utsunomiya, N., Ichioka, K., Matsui, Y., Terai, A., & Arai, Y. (2005). Impact of superficial bladder cancer and transurethral resection on general health-related quality of life: an SF-36 survey. Urology, 65(2), 290–294.

    Article  Google Scholar 

  33. Chung, J., Kulkarni, G. S., Morash, R., Matthew, A., Papadakos, J., Breau, R. H., et al. (2019). Assessment of quality of life, information, and supportive care needs in patients with muscle and non-muscle invasive bladder cancer across the illness trajectory. Supportive Care in Cancer, 27(10), 3877–3885. https://doi.org/10.1007/s00520-019-4649-z.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Hermann, G. G., Mogensen, K., & Rosthoj, S. (2018). Outpatient diode laser treatment of intermediate-risk non-invasive bladder tumors without sedation: efficacy, safety and economic analysis. Scandinavian Journal of Urology. https://doi.org/10.1080/21681805.2018.1450782.

    Article  PubMed  Google Scholar 

  35. Jung, A., Nielsen, M. E., Crandell, J. L., Palmer, M. H., Smith, S. K., Bryant, A. L., et al. (2019). Health-related quality of life among non-muscle-invasive bladder cancer survivors: a population-based study. BJU International.. https://doi.org/10.1111/bju.14888.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Hinojosa-Lindsey, M. (2011). Understanding treatment-related symptoms, symptom management techniques, and symptom management self-efficacy in a sample of non-muscle invasive bladder cancer patients. Dissertation Abstracts International Section B The Sciences and Engineering, 72(1), 214.

    Google Scholar 

  37. Koo, K., Zubkoff, L., Sirovich, B., River, W., Seigne, J., Goodney, P., et al. (2017). The burden of cystoscopic bladder cancer surveillance-anxiety, discomfort, and patient preferences for decision making. Journal of Urology, 197(4), e123.

    Google Scholar 

  38. Kowalkowski, M. A., Chandrashekar, A., Amiel, G. E., Lerner, S. P., Wittmann, D. A., Latini, D. M., et al. (2014). Examining sexual dysfunction in non-muscle-invasive bladder cancer: results of cross-sectional mixed-methods research. Sex Med, 2(3), 141–151. https://doi.org/10.1002/sm2.24.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Mogensen, K., Christensen, K. B., Vrang, M. L., & Hermann, G. G. (2016). Hospitalization for transurethral bladder resection reduces quality of life in Danish patients with non-muscle-invasive bladder tumour. Scand J Urol, 50(3), 170–174. https://doi.org/10.3109/21681805.2015.1132762.

    Article  PubMed  Google Scholar 

  40. Singer, S., Ziegler, C., Schwalenberg, T., Hinz, A., Gotze, H., & Schulte, T. (2013). Quality of life in patients with muscle invasive and non-muscle invasive bladder cancer. Supportive Care in Cancer, 21(5), 1383–1393. https://doi.org/10.1007/s00520-012-1680-8.

    Article  CAS  PubMed  Google Scholar 

  41. Rutherford, C., Costa, D. S. J., King, M. T., Smith, D. P., & Patel, M. I. (2017). A conceptual framework for patient-reported outcomes in non-muscle invasive bladder cancer. Supportive Care in Cancer, 25, 3095–3102. https://doi.org/10.1007/s00520-017-3717-5.

    Article  PubMed  Google Scholar 

  42. Brenner, M. H., Curbow, B., & Legro, M. W. (1995). The proximal-distal continuum of multiple health outcome measures: the case of cataract surgery. Medical Care, 33(4), 236–244.

    Google Scholar 

  43. Rutherford, C., Patel, M. I., Tait, M. A., Smith, D. P., Costa, D. S. J., & King, M. T. (2018). Assessment of content validity for patient-reported outcome measures used in patients with non-muscle invasive bladder cancer: a systematic review. Supportive Care in Cancer, 26(4), 1061–1076. https://doi.org/10.1007/s00520-018-4058-8.

    Article  PubMed  Google Scholar 

  44. Lamm, D. L., Blumenstein, B. A., Crissman, J. D., Montie, J. E., Gottesman, J. E., Lowe, B. A., et al. (2000). Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. Journal of Urology, 163(4), 1124–1129.

    Article  CAS  Google Scholar 

  45. Brausi, M., Oddens, J., Sylvester, R., Bono, A., van de Beek, C., van Andel, G., et al. (2014). Side effects of Bacillus Calmette-Guerin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. European Urology, 65(1), 69–76.

    Article  CAS  Google Scholar 

  46. Mercieca-Bebber, R. L., Price, M. A., Bell, M. L., King, M. T., Webb, P. M., Butow, P. N., et al. (2017). Ovarian cancer study dropouts had worse health-related quality of life and psychosocial symptoms at baseline and over time. Asia-Pacific Journal of Clinical Oncology, 13(5), e381–e388. https://doi.org/10.1111/ajco.12580.

    Article  PubMed  Google Scholar 

  47. Feuerstein, M. A., Jacobs, M., Piciocchi, A., Bochner, B., Pusic, A., Fayers, P., et al. (2015). Quality of life and symptom assessment in randomized clinical trials of bladder cancer: A systematic review. Urologic Oncology, 33(7), 331.e317–323. https://doi.org/10.1016/j.urolonc.2015.04.002.

    Article  Google Scholar 

  48. Kamat, A. M., Sylvester, R. J., Bohle, A., Palou, J., Lamm, D. L., Brausi, M., et al. (2016). Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group. Journal of Clinical Oncology, 34(16), 1935–1944. https://doi.org/10.1200/jco.2015.64.4070.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Coens, C., Pe, M., Dueck, A. C., Sloan, J., Basch, E., Calvert, M., et al. (2020). International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium. Lancet Oncology, 21(2), e83–e96. https://doi.org/10.1016/s1470-2045(19)30790-9.

    Article  PubMed  Google Scholar 

  50. Calvert, M., Kyte, D., Mercieca-Bebber, R., Slade, A., Chan, A. W., King, M. T., et al. (2018). Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension. JAMA, 319(5), 483–494. https://doi.org/10.1001/jama.2017.21903.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Emma Jones, research assistant for help with screening abstracts and full texts against the eligibility criteria.

Funding

Prof Patel was supported by a Cancer Institute NSW Early Career Research Fellowship (10/ECF/2–29). These funds also contributed towards Dr Rutherford’s salary via Sydney University for her time spent undertaking this research.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Claudia Rutherford.

Ethics declarations

Conflict of interest

The authors have no conflicts of interest to declare.

Ethical approval

Ethics approval and consent to participate were not required for this secondary analysis.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary file1 (PDF 277 kb)

Supplementary file2 (PDF 111 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rutherford, C., Patel, M.I., Tait, MA. et al. Patient-reported outcomes in non-muscle invasive bladder cancer: a mixed-methods systematic review. Qual Life Res 30, 345–366 (2021). https://doi.org/10.1007/s11136-020-02637-9

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11136-020-02637-9

Keywords

Navigation